GRENOBLE, France, Feb. 23, 2016 /PRNewswire/ -- ImmunID, the immune companion diagnostics for precision medicine company, today announces that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world’s oldest and largest private cancer center. It has ranked as one of the top two hospitals for cancer care in the United States for more than 25 years.
This new collaboration aims at validating the clinical utility of ImmunID’s ImmunTraCkeR® assay to predict response to cancer immunotherapy and in particular, to immune checkpoint agents in solid tumors. It is based on proof-of-concept results that MSK and ImmunID published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2015, showing that the analysis of peripheral T cell receptor diversity using ImmunTraCkeR® is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma.
Dr Bernhard Sixt, Chairman and Chief Executive Officer of ImmunID, commented: “The expansion of our successful collaboration with MSK as one of the US key cancer centers proves the excitement and potential value of our Predict-ID programs to clinicians.”
Dr Nicolas Pasqual, Co-Founder and Chief Science Officer of ImmunID, added: “This master agreement will allow not only to further validate ImmunTraCkeR®'s predictive power for anti-CTLA4 and anti-PD1 in metastatic melanoma, but also to expand ImmunTraCkeR®'s clinical utility to ‘next-generation’ immuno-oncology approaches and in additional tumor types. We are very proud to be extending our collaboration with Dr Michael Postow and the team of the Melanoma and Immunotherapeutics Service at MSK.”
About ImmunID
ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID’s flagship CE-marked product, ImmunTraCkeR®, evaluates the patient’s immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.
www.immunid.com - Follow ImmunID on Twitter: @ImmunID
About ImmunTraCkeR®
ImmunTraCkeR® is a proprietary CE-marked immune molecular diagnostics assay, which evaluates a patient’s immune status in the blood based on combinatorial T cell diversity. Unlike most companion diagnostics tests, ImmunTraCkeR® is patient-specific rather than drug- or disease-specific, as it approaches the disease from the patient’s own immune system perspective. ImmunTraCkeR® provides information on the patient’s complex immune profile to evaluate clinical benefit or risk under treatment with immunotherapies. ImmunTraCkeR® may ultimately be used as immune companion diagnostics and answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.
Contact
Bernhard Sixt, PhD
Chairman and CEO
Email
Phone: +33 438 785 770
Photo - http://photos.prnewswire.com/prnh/20160222/335827
Photo - http://photos.prnewswire.com/prnh/20160222/335826
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunid-signs-master-collaboration-agreement-with-msk-about-the-prediction-of-response-to-immuno-oncology-agents-using-immuntracker-300224408.html
SOURCE ImmunID
